These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32801102)

  • 21. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
    Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
    Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.
    Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A
    Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures.
    Perucca E; Elger C; Halász P; Falcão A; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2011 Sep; 96(1-2):132-9. PubMed ID: 21680153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.
    Jacobson MP; Pazdera L; Bhatia P; Grinnell T; Cheng H; Blum D;
    BMC Neurol; 2015 Mar; 15():46. PubMed ID: 25880756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety, and tolerability of adjunctive eslicarbazepine acetate in patients with focal to bilateral tonic-clonic seizures.
    Chung S; Guirguis S; Cantu D; Moreira J; Magalhães LM; Hall D; Grinnell T
    Epilepsy Res; 2024 Feb; 200():107285. PubMed ID: 38183687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial.
    Lee SK; Lee SA; Hong SB; Cho YW; Castilla-Fernández G; Fonseca MM; Moreira J; Gama H; Holenz J
    Clin Transl Sci; 2024 May; 17(5):e13802. PubMed ID: 38787305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
    Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
    Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time to sustained responder status in patients with focal seizures treated with adjunctive eslicarbazepine acetate.
    Cantu D; Pereira A; Hall D; Grinnell T
    Epilepsy Res; 2023 Dec; 198():107262. PubMed ID: 38035455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures.
    Costa R; Steinhoff B; Gama H; Ikedo F; Rocha JF; Soares-da-Silva P
    Drugs Aging; 2018 Dec; 35(12):1109-1117. PubMed ID: 30387043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18-59 years) adults.
    Andermann E; Rosenfeld W; Penovich P; Rogin J; Cendes F; Carreño M; Ramsay RE; Ben-Menachem E; Gama H; Rocha F; Soares-da-Silva P; Tosiello R; Blum D; Grinnell T
    Epilepsy Res; 2021 Jan; 169():106478. PubMed ID: 33338829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.
    Shorvon SD; Trinka E; Steinhoff BJ; Holtkamp M; Villanueva V; Peltola J; Ben-Menachem E
    J Neurol; 2017 Mar; 264(3):421-431. PubMed ID: 28101651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapy.
    Holtkamp M; McMurray R; Bagul M; Sousa R; Kockelmann E
    Acta Neurol Scand; 2016 Jul; 134(1):76-82. PubMed ID: 26915469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
    Ben-Menachem E; Gabbai AA; Hufnagel A; Maia J; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2010 May; 89(2-3):278-85. PubMed ID: 20299189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of seizure exacerbation and seizures reported as adverse events during adjunctive treatment with eslicarbazepine acetate: A pooled analysis of three Phase III controlled trials.
    Carreño M; Benbadis S; Rocha F; Blum D; Cheng H;
    Epilepsia Open; 2017 Dec; 2(4):459-466. PubMed ID: 29588976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures.
    Mintz M; Pina-Garza JE; Wolf SM; McGoldrick PE; Józwiak S; Grinnell T; Cantu D; Costa R; Moreira J; Li Y; Blum D
    J Child Neurol; 2020 Mar; 35(4):265-273. PubMed ID: 31878820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative economic outcomes in patients with focal seizures initiating eslicarbazepine acetate versus brivaracetam as their first adjunctive ASD.
    Mehta D; Davis M; Epstein AJ; Wensel B; Grinnell T; Thach A; Williams GR
    J Med Econ; 2021; 24(1):939-948. PubMed ID: 34311671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetics and Exposure-Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial-Onset Seizures.
    Sunkaraneni S; Ludwig EA; Passarell JA; Blum D; Grinnell T; Fiedler-Kelly J
    J Clin Pharmacol; 2018 Jul; 58(7):927-938. PubMed ID: 29528499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis.
    Lattanzi S; Trinka E; Zaccara G; Striano P; Russo E; Del Giovane C; Silvestrini M; Brigo F
    Drugs; 2022 Feb; 82(2):199-218. PubMed ID: 35061214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro-Esli.
    Holtkamp M; Delanty N; Sales F; Serratosa J; McMurray R; Villanueva V
    Acta Neurol Scand; 2019 Jan; 139(1):49-63. PubMed ID: 30176048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies.
    Sperling MR; French J; Jacobson MP; Pazdera L; Gough M; Cheng H; Grinnell T; Blum D;
    Neurology; 2016 Mar; 86(12):1095-102. PubMed ID: 26911639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.